Jupiter Topco LLC bought a new stake in Septerna, Inc. (NASDAQ:SEPN – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,307,500 shares of the company’s stock, valued at approximately $43,723,000. Jupiter Topco LLC owned approximately 2.80% of Septerna as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also bought and sold shares of SEPN. Elmind Capital LP purchased a new position in Septerna in the second quarter worth about $1,655,880,000. ADAR1 Capital Management LLC bought a new stake in shares of Septerna in the 2nd quarter valued at approximately $31,506,000. Primecap Management Co. CA purchased a new position in shares of Septerna in the 2nd quarter worth approximately $39,096,000. Canada Pension Plan Investment Board bought a new position in shares of Septerna during the 2nd quarter valued at approximately $298,000. Finally, Legal & General Group Plc purchased a new stake in Septerna during the 2nd quarter valued at $337,000.
Septerna Trading Up 0.5%
SEPN opened at $40.47 on Friday. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of -74.94 and a beta of 2.29. Septerna, Inc. has a 12-month low of $11.70 and a 12-month high of $51.10. The business’s fifty day simple moving average is $37.24 and its 200-day simple moving average is $30.75.
Analyst Ratings Changes
A number of research analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research note on Friday, July 17th. Raymond James Financial reissued a “strong-buy” rating and set a $49.00 price target on shares of Septerna in a research note on Tuesday, August 11th. JonesTrading boosted their price objective on Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Wells Fargo & Company upped their price objective on Septerna from $48.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Finally, Truist Financial increased their target price on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $52.44.
Check Out Our Latest Research Report on SEPN
Insider Buying and Selling at Septerna
In other news, insider Samira Shaikhly sold 6,250 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $35.08, for a total transaction of $219,250.00. Following the transaction, the insider directly owned 793 shares in the company, valued at approximately $27,818.44. This trade represents a 88.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Daniel D. Long sold 15,000 shares of Septerna stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $35.51, for a total transaction of $532,650.00. Following the transaction, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,423,590.12. The trade was a 13.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 61,030 shares of company stock valued at $2,329,666. Company insiders own 5.80% of the company’s stock.
Septerna Profile
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.
Featured Articles
- Five stocks we like better than Septerna
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.